Chembio Diagnostics Announces CE Mark for DPP SARS-CoV-2 Antigen and IgM/IgG Test Systems - Seite 3

All DPP tests are developed and manufactured in the United States and are the subject of a range of domestic and global patents and patents pending.

About Chembio Diagnostics
Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Coupled with Chembio’s extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at www.chembio.com.

About Luas Diagnostics:
Luas Diagnostics is based in Guildford, Surrey and is a UK registered private company, which was founded in 2020. Using enzymes, Luas Diagnostics has developed a new class of sensors that generate electric current upon encountering their molecular target, allowing the development of biomarker assays that are an order of magnitude faster, more versatile, and cheaper to build than current systems in the market. Because Luas Diagnostics’ diagnostic tests do not require preparation, washing steps, or complex reading mechanisms, the tests can be miniaturized and coupled to a smartphone via Bluetooth for easy readout and uploading of data to repositories in the cloud.

DPP is Chembio’s registered trademark, and the Chembio logo is Chembio’s trademark. For convenience, these trademarks appear in this release without or symbols, but that practice does not mean that Chembio will not assert, to the fullest extent under applicable law, its rights to the trademarks.

Contact:  
Philip Taylor
Gilmartin Group
[phone]
[e-mail]